The Clear Route

Since we started publishing nearly a year ago, events have led us to repeatedly analyze issues related to how companies build corporate value and how they can show investors a return on investment.

In the standard model, valuation starts out low and increases in a steepening curve as companies hit milestones, typically represented by different stages of preclinical and clinical development, that act as signals of diminishing risk...